Generic Fentora Doesn't Violate Teva IP, Fed. Circ. Finds

Law360, New York (February 14, 2013, 4:52 PM EST) -- The Federal Circuit on Thursday revived two patents held by a Teva Pharmaceutical Industries Ltd. subsidiary covering the painkiller Fentora, but affirmed a lower court's finding that Actavis Inc.'s bid to market a generic version of the drug doesn't violate the patents.

In a unanimous decision, a three-judge panel said Actavis, formerly Watson Pharmaceuticals Inc., failed to show by clear and convincing evidence that the patents, asserted by Teva unit Cephalon Inc., require “undue experimentation” to practice the claimed invention which relates generally to the administration...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.